Cartherics is seeking a Research Assistant to help assist
with the technology (primarily tissue culture and flow cytometry) underpinning its very active research program in Chimeric
Antigen Receptor (CAR) -T based immunotherapies. CAR-T cells have rapidly
evolved as a revolution in anti-cancer treatments.
Cartherics has two fundamental T cell based platforms.
The first is to expand in tissue culture conditions, sufficient numbers of human
blood T cells having a T cell receptor (TCR) specific for a particular cancer
antigen. Their function will be initially tested by in vitro cell cytotoxicity
assays. These will then be infused into patients bearing that cancer, in a
Phase I trial to demonstrate both safety and also any potential anti-cancer
efficacy. If successful these cells can then be genetically engineered to
express additional CAR’s encompassing antibodies to other cancer antigens to enhance
their killing efficacy. The second platform is to use induced pluripotential
stem cells (iPSC) to embed a TCR specificity. These T-iPSC will then be
transfected with specific CAR’s encoded within viral vectors, and induced to
differentiate into cytotoxic T cells.
A central part of these projects is the tissue culture
maintenance of cell lines, assistance in induction of T cell differentiation
and cellular analysis by flow cytometry. The successful applicant will thus have
a strong background in immunology related tissue culture and phenotypic and
functional characterisation of different cell types – preferably human T cells.
They will have a passion for the highest standards of laboratory practice and
maintenance and enjoy working in a very active team of Post Doctoral Fellows
and research technicians.
Education/Qualifications
The
appointee will have an appropriate undergraduate or post graduate degree and experience
as a research assistant.
Company Description
Cartherics Pty Ltd is an exciting
new Melbourne-based start-up biotechnology company, developing the next
generation immune therapeutic approach to treat cancer. The Company’s objective
is to identify and expand T cells with their own cancer recognizing T Cell
Receptors (TCRs), then use sophisticated molecular engineering to empower these
cells with additional cancer-specific recognition and activation molecules
(CAR-T). Cartherics will use stem cell technology to exponentially expand these
“cancer smart” killer cells. The laboratories will be located within the
stunning new facilities of the Monash Health Translation Precinct.
Send
application with C.V including potential referees to:
Professor
Richard Boyd
Chief
Scientific Officer,
Cartherics,
Pty Ltd.
Telephone
inquiries +61 419 317 533
No comments:
Post a Comment